[HTML][HTML] Immune system response during viral Infections: Immunomodulators, cytokine storm (CS) and Immunotherapeutics in COVID-19

FH Pottoo, T Abu-Izneid, AM Ibrahim, MN Javed… - Saudi pharmaceutical …, 2021 - Elsevier
Coronaviruses are non-segmented and single stranded positive-sense RNA (+ ssRNA)
viruses. To date, 06 human coronaviruses (HCoVs) are reported; α-CoVs (HCoVs-NL63 and …

[HTML][HTML] Adjunct immunotherapies for the management of severely ill COVID-19 patients

SR Bonam, SV Kaveri, A Sakuntabhai, L Gilardin… - Cell Reports …, 2020 - cell.com
Coronavirus disease 2019 (COVID-19) is caused by severe acute respiratory syndrome
coronavirus 2 (SARS-CoV-2). It has infected millions, with more than 275,000 fatal cases as …

Immunomodulatory-based therapy as a potential promising treatment strategy against severe COVID-19 patients: A systematic review

M Razmi, F Hashemi, E Gheytanchi… - International …, 2020 - Elsevier
The global panic of the novel coronavirus disease 2019 (COVID-19) triggered by the severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has led to an urgent requirement …

Cytokine storm in COVID-19: pathogenesis and overview of anti-inflammatory agents used in treatment

M Soy, G Keser, P Atagündüz, F Tabak… - Clinical …, 2020 - Springer
COVID-19 infection has a heterogenous disease course; it may be asymptomatic or causes
only mild symptoms in the majority of the cases, while immunologic complications such as …

Cytokine storm in COVID-19 and the treatment simulacrum

A Karimi, SMR Hashemian - Biomedical and Biotechnology …, 2020 - journals.lww.com
Following the outbreak of the severe acute respiratory syndrome-coronavirus (SARS-CoV-2)
in December 2019 at Wuhan, China, it spread through the world rapidly, and this disease …

Molecular pathogenesis, immunopathogenesis and novel therapeutic strategy against COVID-19

SK Chatterjee, S Saha, MNM Munoz - Frontiers in molecular …, 2020 - frontiersin.org
The coronavirus disease 2019 (COVID-19), is a highly contagious transmittable disease
caused by a recently discovered coronavirus, pathogenic SARS-CoV-2. Followed by the …

Immunomodulatory drugs in the management of SARS-CoV-2

DR Burrage, S Koushesh, N Sofat - Frontiers in immunology, 2020 - frontiersin.org
With the onset of the global pandemic in 2020 of Severe Acute Respiratory Syndrome
Coronavirus-2 (SARS-CoV-2), there has been increasing research activity around certain …

Prospects of novel and repurposed immunomodulatory drugs against acute respiratory distress syndrome (ARDS) associated with covid-19 disease

SS Nayak, A Naidu, SL Sudhakaran, S Vino… - Journal of personalized …, 2023 - mdpi.com
Acute respiratory distress syndrome (ARDS) is intricately linked with SARS-CoV-2-
associated disease severity and mortality, especially in patients with co-morbidities. Lung …

[HTML][HTML] Role of monoclonal antibody drugs in the treatment of COVID-19

C Ucciferri, J Vecchiet, K Falasca - World journal of clinical cases, 2020 - ncbi.nlm.nih.gov
Currently clinicians all around the world are experiencing a pandemic caused by severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The clinical presentation of this …

Immunomodulation as a potent COVID-19 pharmacotherapy: Past, present and future

DM Hertanto, BS Wiratama, H Sutanto… - Journal of …, 2021 - Taylor & Francis
In the first year of its appearance, the 2019 coronavirus disease (COVID-19) has affected
more than 150 million individuals and killed 3 million people worldwide. The pandemic has …